Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
In patients with thalassemia major (TM) who are non-compliant with long-term desferrioxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional hemosiderosis. Combined chelation therapy with DFO and deferiprone has maximized the efficacy of the therapy and reduced cardiological complications. The aim of this report is to present the results of this combination in a desperate case of heart failure.
Tsironi
M
M
First Department of Internal Medicine, University of Athens, Athens, Greece. gpoyl@otenet.gr
Deftereos
S
S
Andriopoulos
P
P
Farmakis
D
D
Meletis
J
J
Aessopos
A
A
D000328:Adult; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage*; D017086:beta-Thalassemia / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine